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Abstract
BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is common, yet no curative treatment 
identified. Cinnamon is a herbal substance, which has many applications in medicine.
AIM: The aim of the study was to study the effect of cinnamon on patients with chronic pelvic pain syndrome.
METHODS: Sixty patients with documented CP/CPPS randomized into two groups during 2018 and 2019 in 
Baghdad. The first group received 60 capsules each contained 1 g of cinnamon. The other group received 60 
capsules each contained 1 g of sugar powder (placebo). All the patients instructed to take one capsule twice daily for 
1 month. National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) was reported for both groups 
at baseline and after 1 month of treatment. The primary outcome was a patient perceivable improvement defined as 
a reduction of the NIH-CPSI by 6 or more points after 1 month, whereas improvement of sub-scores of NIH-CPSI 
(pain, urinary symptoms, and quality of life) considered as a secondary outcome, and adverse reactions reported.
RESULTS: Thirteen patients (43.3%) of the cinnamon group have 6 or more points of reduction in the total NIH-CPSI 
compared to four patients (13.3%) of the control groups (p = 0.01). The improvement in total NIH-CPSI score was 
mainly due to improvement in pain sub-score, whereas in urinary symptoms, there was marginal change with no 
significant change in the quality of life score. The only reported side effect was gastric upset in one patient.
CONCLUSION: The study concluded that cinnamon improves NIH-CPSI in patients with CP/CPPS.
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Introduction
National Institutes of Health (NIH) defines 
chronic prostatitis/chronic pelvic pain syndrome (CP/
CPPS) as the presence of genitourinary pain in 
the absence of uropathogenic bacteria detected by 
standard microbiologic methodology [1], [2], [3].
The presence of symptoms resembling that 
of CP/CPPS in different population fall in the range 
between 2.2% and 9.7% with a mean prevalence 
of 8.2%, making CP/CPPS as one of common 
urologic problems. Nevertheless, its etiology and 
pathophysiology are poorly understood with no solid 
guidelines for effective treatment [4], [5].
Prolonged period of antibiotic therapy is usually 
used as the first line in the treatment of CP/CPPS in 
the first place regardless of the finding of prostatic 
fluid microscopic examination and culture. When this 
approach fails, the next option of managements which 
have been tried and investigated include medications 
such as alpha-blockers, anti-inflammatory drugs, 
muscle relaxants, anticonvulsants, phosphodiesterase 
type 5 inhibitors or even hormonal manipulation, also 
physiotherapy, behavioral therapy, herbal, or even 
surgical interventions. Despite the multiplicity of the 
treatment options, none of these options proved 
curative for all patients with CP/CPPS. Therefore, the 
trial of different treatment options in the hope of finding 
effective treatment is justifiable [6], [7].
Cinnamon is the bark of trees belonging to the 
genus Cinnamomum. It is an aromatic spice that is used 
in traditional medicine for multiple purposes, including 
relieving of pain. Cinnamon is also proved to have an 
antibacterial effect (Figure 1) [8], [9], [10].
Cinnamon has a well-known scent due to 
its oil content, which has a high concentration of 
cinnamaldehyde in addition to several other compounds 
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such as cinnamyl acetate, L-borneol, caryophyllene 
oxide, eugenol, b-caryophyllene, L-bornyl acetate, 
E-nerolidol, α-terpineol, α-cubebene, terpinolene, 
and α-thujene. Besides, cinnamon contains a variety 
of resinous compounds, including cinnamate and 
cinnamic acid [11, [12], [13].
Cinnamon has been long used in kitchens as 
spice and appetizer without reported serious adverse 
events. The beneficial health attributes of cinnamon 
and its derivative and components reported by several 
researchers. These include its antimicrobial, anti-
inflammatory, antioxidant, anti-diabetic, analgesic, 
and even anticancer properties. Nevertheless, further 
studies are still required to illuminate the potential 
health benefits of the spice [14], [15], [16], [17], [18].
The “National Institutes of Health Chronic 
Prostatitis Symptom Index” (NIH-CPSI) is developed 
as a tool to assess the severity of symptoms of CP/
CPPS [19].
A reduction of 6 or more points in the NIH-CPSI 
score showed to be clinically perceivable difference by 
the patients in the previous studies [20].
A validated Arabic version of NIH-CPSI 
showed “excellent internal consistency” and correlates 
well with the severity of symptoms in patients with CP/
CPPS [21].
This study is designed to observe the effect 
of cinnamon on patients with chronic pelvic pain 
syndrome.
Materials and Methods
Ethical approval and registration
The study approved by the Scientific Unit 
and Medical Ethics Committee at Al Kindy College of 
Medicine, University of Baghdad and had the approval 
number: 165.10/04/2019.
The study registered on ClinicalTrials.gov with 
the ID: NCT03946163.
Sample size
For pilot trials sample size estimation, the rules 
of thumb can be simply applied, Browne RH states 
a general role: “Use at least 30 subjects or greater to 
estimate a parameter,” whereas Julious SA proposes 
12 subjects per intervention arm to be the minimal 
acceptable sample size. This study intended for a sample 
size of 30 patients on each arm of the study [22], [23].
Patients inclusion
This placebo-controlled clinical trial included 
60 patients diagnosed with CP/CPPS with a minimum 
duration of symptoms of 6 months. All recruited from 
the urology outpatient clinic in Al-Kindy Teaching 
Hospital in Baghdad in the period from February 1, 
2018, to June 30, 2019. From all of the patients, clinical 
history was taken and proper physical examination was 
performed. Relevant investigations obtained including 
ultrasonography of abdomen and pelvis, urinalysis, and 
culture and sensitivity for initial, midstream, and post-
prostatic massage urine sample (or expressed prostatic 
secretions when available), serum prostate-specific 
antigen, and investigations for sexually transmitted 
diseases performed when relevant.
Patients with food allergies, previous 
transurethral intervention, positive urine culture or 
positive prostatic secretions culture, uncontrolled 
medical diseases (such as diabetes, hypertension, 
or asthma), or patients using analgesics for other 
conditions (such as musculoskeletal pain) were 
excluded from the study sample.
All the patients received before inclusion in 
the study at least 3 months coarse of oral antibiotics, 
some of them were treated with alpha-blockers, 
anticholinergic drugs or both, others tried nonsteroidal 
anti-inflammatory drugs, all of the patients had partial or 
no improvement to previous treatments, none of them 
have complete resolution of the condition. At the time of 
inclusion, the patients were off any other treatment for 
their condition for at least 1 month.
Written informed consent signed by all of the 
patients.
Any patient aged more than 18 years was 
eligible for the study as far as he can approve his 
participation in the study; there was no upper limit for 
the ages of the participants
Study protocol
The patients were randomized into two 
groups by flipping a coin for each new odd-numbered 
participant to assign him to one of the two groups; 
the next participant was automatically assigned to the 
other group. Each patient in the first groups received 60 
capsules, each capsule contained 1 g of cinnamon bark Figure 1: Cinnamon barks (a) and powder (b)
ba
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powder and instructed to take one capsule twice daily 
for 1 month. Whereas each patient in the other group 
received 60 capsules similar to those given to the first 
group in shape, size, color, and smell containing 1 g of 
sugar powder as a placebo and instructed to take one 
capsule twice daily for 1 month. The compliance of the 
patients with the treatment was measured by counting 
the residual capsule after conclusion of the study period.
Each patient filled a written validated 
questionnaire of translated NIH-CPSI (Arabic version) 
before starting treatment and 1 month later. Each patient 
on the questionnaire can score a total of (0–43) (the 
higher the score, the more severe are the symptoms). 
The total score divided into three sub-scores for the 
following domains: Pain (0–21), urinary symptoms 
(0–10), and quality of life (0–12) [21].
Any complaints of the patients from the drug 
or unwanted effects were reported as adverse effects.
The study was triple blinded; the patients, 
the researchers, and the statistical investigator all 
were blinded to the content of the capsules until the 
conclusion of the study.
Outcome measures
A reduction in the NIH-CPSI score of six or 
more points from the initial score (a patient perceivable 
improvement) considered as a positive response (the 
primary outcome). A reduction in the total NIH-CPSI or 
in one or more of its sub-scores dealt with as a minor 
positive response (secondary outcome). The adverse 
effects were reported.
Statistical analysis
The data were analyzed using SPSS version 
16 using descriptive statistics for all variables, 
independent t-test to compare both groups before the 
intervention, covariance analysis to analyze continuous 
variables regarding the effect of the intervention on 
both groups, and Chi-square test to analyze categorical 
variable regarding the effect of the intervention on both 
groups. p < 0.05 was considered significant.
Results
Of the 64 patients recruited for the clinical trial, 
four patients were excluded: One due to food allergy, 
two patients were excluded one due to uncontrolled 
chronic obstructive airway disease and the other due 
to uncontrolled diabetes mellitus, another patient 
decline to participate in the clinical trial. The remaining 
60 patients randomized into two groups, 30 patients in 
each group (Figure 2).
Table 1: Patients’ age and duration of complaint of studied 
subjects according to the group of study
Group Group n Mean SD p-value*
Age (years) Control 30 37.2 11.04 0.927
Cinnamon 30 37.0 8.51
Total 60
Duration (months) Control 30 13.3 8.18 0.674
Cinnamon 30 12.6 4.77
Total 60
*Statistical tests used an independent t-test. Significant p<0.05.
There was no significant difference between 
the two groups regarding the age, duration of symptoms 
(Table 1), total NIH-CPSI score, and individual NIH-
CPSI sub-scores (Table 2).
Table 2: Pain, urinary symptoms, quality of life, and NIH-CPSI 
scores of studied subjects before intervention according to 
the group of study
Group Group n Mean SD p value
Pain Control 30 11.1 4.55 0.704*
Cinnamon 30 10.6 4.90
Urinary symptoms Control 30 5.8 3.15 0.141*
Cinnamon 30 4.7 2.71
Quality of life Control 30 6.7 3.29 0.354*
Cinnamon 30 6.0 2.63
NIH-CPSI Control 30 23.7 8.69 0.273*
Cinnamon 30 21.3 7.61
*Statistical tests used a two sample t-test. Significant p<0.05. NIH-CPSI: National Institutes of Health-
Chronic Prostatitis Symptom Index.
In the cinnamon group, 13 (43.3%) subjects 
had six or more points of reduction (patient perceivable 
improvement) in the total NIH-CPSI compared to 4 
(13.3%) subjects in the control group, making the primary 
response in the cinnamon group more significant than that 
of the control group with p = 0.01. The overall reduction 
in NIH-CPSI score was significantly observed in the 
cinnamon group compared to the control group (Table 3).
Table 3: Association between cinnamon treatment and primary 
response
Group Yes No p value* Odds 
ratio
95% Confidence 
intervaln Percentage n percentage
Cinnamon
Control
13
4
43.3
13.3
17
26
56.7
86.7
0.010 4.4971 1.387,17.816
*X2df1=6.648.
On the level of individual domain score, 
there was significant reduction in the pain score in the 
cinnamon groups compared to the control group. On 
the other hand, decrement of urinary symptoms in the 
control group with increment in the cinnamon group 
made a significant difference between the two groups 
(Table 4).
The quality of life score was improved 
(decreased) for both groups, but more prominent in the 
cinnamon group, yet the difference was not statistically 
significant (Table 4).
One subject from the cinnamon group reported 
gastric upset (acidity) and treated by antacid. No other 
side effect was reported in both groups.
Discussion
Cinnamon produced perceivable improvement 
in patients with CP/CPPS by reducing mainly the pain 
Figure 2: CONSORT flowchart of the research plan
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increases the urinary symptoms score. The only 
reported that side effect was gastrointestinal upset.
score on the NIH-CPSI and hence the total score, yet it 
does not affect the quality of life score and it marginally 
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The proposed etiology of CP/CPPS includes 
infection, inflammation, hormonal, and neuronal 
reasons or even autoimmunity may contribute to the 
development of CP/CPPS [24].
Proper management of CP/CPPS has always 
been a challenging task due to elusive etiological 
mechanisms [25].
Effect of cinnamon on pain was reported for 
perineal and pelvic pain in the previous studies and 
found to produce a noticeable improvement in primary 
dysmenorrhea and after episiotomy [17], [18], [26], [27].
Cinnamon essential oil possesses anti-
nociceptive properties. Its potency in chronic pain 
inhibition was similar to diclofenac, though its acute anti-
nociceptive effect reported to be less than morphine in 
mice [28].
Cinnamon extract in high doses decreased the 
chronic pain intensity in animal studies [28], [29].
The pain-reducing action found in this 
study is consistent with that found in other studies. 
Jaafarpour et al. in 2015 and Jahangirifar et al. in 
2018 both found that cinnamon significantly reduces 
the pain of primary dysmenorrhea. Mohammadi et al. 
in 2014 found that the local use of cinnamon ointment 
improves healing and reduces the pain of episiotomy 
incisions [17], [18], [26], [27].
Dashti-Rahmatabadi et al. in 2009 found that 
cinnamon extract in high dose decreases the intensity 
of chronic formalin-induced pain in rats [29].
Cinnamon has documented anti-inflammatory 
effect probably through anti-complement activity and 
inhibition of complement-dependent inflammatory 
cascade [30], [31].
Antioxidant activity of cinnamon extracts, 
its essential oil, and eugenol (one of its components) 
documented in vitro using an oxidative β-carotene/
linoleic acid system, peroxynitrite-induced nitration, 
lipid peroxidation, and 1,1-diphenyl-2-picrylhydrazine 
test [32], [33], [34], [35], [36].
Thermo-sensitive transient receptor potential 
(TRP) channels, especially TRPV1 and TRPA1, are 
activated by the pungent compounds present in 
spices. Studies showed that TRPA1 agonists such 
cinnamaldehyde, the pungent ingredients in cinnamon 
activate the sensory nerves and induce adrenaline 
secretion through the central nervous system [37].
Furthermore, linalool is one of the monoterpene 
compounds in cinnamon that affects pain receptors 
and causes analgesia. Linalool creates inhibitory 
capability in the central nervous system neurons by 
opening potassium channels. Phenols like eugenol 
inhibit calcium entrance inside the cell and so control 
the release of neurotransmitters interfering in pain from 
terminals of afferent fibers in the posterior horn of the 
spinal cord [29], [38].
The pain-relieving properties of cinnamon 
can be the result of its anti-inflammatory, anti-
oxidant, TRPA1-activation-induced central 
adrenaline secretion, linalool central nervous system 
inhibitory properties, eugenol pain transfer inhibitory 
properties, or the combination of some, or all of the 
above [29], [32], [33], [34], [35], [36], [37], [38].
The minor increment in urinary symptoms 
sub-score is probable due to the pungent effect of 
cinnamaldehyde; the aromatic compound of cinnamon.
Spicy food found to aggravate symptoms in 
CP/CPPS by Herati et al., although the paper they 
published did not demonstrate the change in specific 
domains in NIH-CPSI [39].
Tripp et al. in 2004 reported that the quality of 
life in patients with CP/CPPS correlated directly with 
both pain and urinary symptoms, with pain being the 
most “robust predictor” for the quality of life in these 
patients [40].
The quality of life improved more for the 
cinnamon group, but not to the point of statistical 
significance. This can be explained by the improvement 
of pain accompanied by worsening of urinary symptoms.
The side effect of cinnamon reported in this 
study is expected since self-limiting gastrointestinal 
adverse events are the most commonly reported side 
effect of cinnamon [41].
The study limited by the relatively short period 
of follow-up, a longer period of follow-up to observe the 
consistency of the change in symptoms would provide a 
more reliable outcome. Another limitation is the number 
of the recruited patients; although based on reliable 
literature, a larger number of patients would provide 
more power to the study. Another limitation of this study 
is the use of the translated version of the NIH-CPSI, the 
validation of the translated version does not make the 
perception of the patient to the questionnaire as that of 
the native English speaker to the English version, but 
Table 4: The effect of cinnamon treatment in comparison with placebo on total NIH-CPSI score, pain score, urinary symptoms 
score, and quality of life score
Score Group n Estimated baseline 
mean
Estimated end line 95% Confidence 
interval
Outcome 
(Endline-baseline)
% of 
difference
p value
Mean SE
NIH-CPSI Control 30 22.53 19.99 0.616 18.765, 21.230 −2.54 −12.71 0.007*
Cinnamon 30 17.53 0.616 16.303, 18.768 −5.00 −28.52
Pain Control 30 10.87 9.395 0.382 8.63, 10.159 −1.48 −15.70 0.001*
Cinnamon 30 6.305 0.382 5.541, 7.070 −4.57 −72.40
Urinary symptoms Control 30 5.27 4.87 0.223 4.421, 5.315 −0.40 −8.21 0.005*
Cinnamon 30 5.80 0.223 5.789, 6.245 0.53 9.14
Quality of life score Control 30 6.40 5.80 0.224 5.349, 6.247 −0.60 −10.34 0.183*
Cinnamon 30 5.37 0.224 4.920, 5.818 −1.03 −19.18
*Statistical tests used a covariance analysis. Significant p<0.05.
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it gives acceptable reliability to the results of the score 
obtained from it.
Conclusion
Cinnamon produces patient-perceivable 
improvement in symptoms of patients with CP/CPPS. 
For these patients, cinnamon reduces the total NIH-
CPSI significantly through reduction of pain, yet it 
probably affects the urinary symptoms adversely and 
does not affect the quality of life significantly, whereas 
the side effects are minor and tolerable.
We recommend further studies on a larger 
group of patients with CP/CPPS to confirm the 
beneficial effect of cinnamon with the early exclusion of 
those who have worsening of their urologic symptoms. 
Besides, cinnamon contains multiple active ingredients, 
the study of separate, isolated chemicals extracted 
from cinnamon may prove better improvement with 
less adverse effects, further isolation, and study of each 
ingredient alone is a noteworthy recommendation.
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